Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers.
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings.
Compared to chemotherapy alone, amivantamab plus chemotherapy had a better objective response rate and prolonged progression-free survival and overall survival.